[{"address1": "1111 Kane Concourse", "address2": "Suite 301", "city": "Bay Harbor Islands", "state": "FL", "zip": "33154", "country": "United States", "phone": "781 652 4500", "website": "https://www.avenuetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lindsay Allan Rosenwald", "age": 68, "title": "Executive Director", "yearBorn": 1955, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 4.4, "open": 4.3, "dayLow": 4.12, "dayHigh": 4.37, "regularMarketPreviousClose": 4.4, "regularMarketOpen": 4.3, "regularMarketDayLow": 4.12, "regularMarketDayHigh": 4.37, "beta": -0.098, "forwardPE": -0.14954956, "volume": 80762, "regularMarketVolume": 80762, "averageVolume": 58852, "averageVolume10days": 243170, "averageDailyVolume10Day": 243170, "bid": 4.1, "ask": 4.33, "bidSize": 100, "askSize": 100, "marketCap": 2471424, "fiftyTwoWeekLow": 4.04, "fiftyTwoWeekHigh": 93.75, "fiftyDayAverage": 9.9279, "twoHundredDayAverage": 27.5571, "currency": "USD", "enterpriseValue": -261914, "floatShares": 521224, "sharesOutstanding": 595524, "sharesShort": 2580, "sharesShortPriorMonth": 4178, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0044, "heldPercentInsiders": 0.11663, "heldPercentInstitutions": 0.0293, "shortRatio": 0.19, "shortPercentOfFloat": 0.0044, "impliedSharesOutstanding": 595524, "bookValue": 4.635, "priceToBook": 0.89536136, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": 0.113, "netIncomeToCommon": -10377000, "trailingEps": -73.5, "forwardEps": -27.75, "lastSplitFactor": "1:75", "lastSplitDate": 1714089600, "52WeekChange": -0.9480438, "SandP52WeekChange": 0.26430142, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ATXI", "underlyingSymbol": "ATXI", "shortName": "Avenue Therapeutics, Inc.", "longName": "Avenue Therapeutics, Inc.", "firstTradeDateEpochUtc": 1498570200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ab3c15b5-e280-3b5c-b842-8e87c6276492", "messageBoardId": "finmb_310815442", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.15, "targetHighPrice": 56.25, "targetLowPrice": 56.25, "targetMeanPrice": 56.25, "targetMedianPrice": 56.25, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 1783000, "totalCashPerShare": 3.021, "quickRatio": 1.491, "currentRatio": 1.547, "returnOnAssets": -2.09028, "returnOnEquity": -5.35102, "freeCashflow": -13494500, "operatingCashflow": -9451000, "earningsGrowth": -0.763, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-10"}]